Non Alcoholic Fatty Liver Disease Stocks List

Non Alcoholic Fatty Liver Disease Stocks Recent News

Date Stock Title
Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Nov 20 IVA Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Nov 20 IVA Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Nov 20 BLTE Belite Bio: Interesting Science, But Quite A Few Worries
Nov 19 ALGS Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Nov 18 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Nov 18 AKRO Akero a new buy at Citi on liver disease asset
Nov 18 GALT Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Nov 18 SGMT Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Nov 18 SGMT Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Nov 18 IVA The first MASH drug could open the door for others — including GLP-1s
Nov 15 IVA Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Nov 15 AKRO Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Nov 15 ETNB 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
Nov 14 SGMT Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14 SGMT Sagimet Biosciences GAAP EPS of -$0.45
Nov 14 GALT Galectin Therapeutics GAAP EPS of -$0.18
Non Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.

Browse All Tags